Intelligence Feed event · Equity · 2026-10-06

    Spyre Therapeutics prices $350M public offering at $85 per share for Phase 3 readiness

    Question

    Spyre Therapeutics prices $350M public offering at $85 per share for Phase 3 readiness

    Direct answer

    Spyre Therapeutics announced the pricing of a $350 million underwritten public equity offering at an issuance price of $85 per share. The financing proceeds are allocated toward advancing clinical-stage immunology pipelines spanning gastroenterology, rheumatology, and dermatology, specifically funding Phase 3 operational readiness.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-06
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Spyre Therapeutics prices $350M public offering at $85 per share for Phase 3 readiness”, revision 1, evidence through 2026-10-06. https://marketontology.com/market-events/2026-10-06/spyre-therapeutics-prices-350m-public-offering-at-85-per-share-for-phase-3-readi-59e768

    EQUITY
    Spyre Therapeutics prices $350M public offering at $85 per share for Phase 3 readiness
    Spyre Therapeutics announced the pricing of a $350 million underwritten public equity offering at an issuance price of $85 per share. The financing proceeds are allocated toward advancing clinical-stage immunology pipelines spanning gastroenterology, rheumatology, and dermatology, specifically funding Phase 3 operational readiness.
    SYRE
    Impact
    65
    OCT 6
    SIG
    90%
    SYRE
    Spyre Therapeutics prices $350M public offering at $85 per share for Phase 3 readiness
    Spyre Therapeutics announced the pricing of a $350 million underwritten public equity offering at an issuance price of $85 per share. The financing proceeds are allocated toward advancing clinical-stage immunology pipelines spanning gastroenterology, rheumatology, and dermatology, specifically funding Phase 3 operational readiness.
    → Direct equity issuance at $85 per share introduces immediate supply overhang while extending operating runway into Phase 3 clinical trials.
    Impact
    Spyre Therapeutics announced the pricing of a $350 million underwritten public equity offering at an issuance price of $85 per share. The financing proceeds are allocated toward advancing clinical-stage immunology pipelines spanning gastroenterology, rheumatology, and dermatology, specifically funding Phase 3 operational readiness.
    Affected
    SYRE
    Transmission
    Direct equity issuance at $85 per share introduces immediate supply overhang while extending operating runway into Phase 3 clinical trials.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SYREshare dilution offset by multi-year clinical trial fundingMixed1-5dPriced $350 million public offering of common stock at $85 per share.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month